Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the primary-line treatment method of CML-CP. 5 hundred and nineteen sufferers with recently diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of one hundred mg after every day (259 individuals) https://michaelm419chl2.theblogfairy.com/profile